Metformin-induced RBMS3 expression enhances ferroptosis and suppresses ovarian cancer progression
Reproductive Biology · 2025-03 · 25 (1) · 100968
DOI: 10.1016/j.repbio.2024.100968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive Biology, 2025-03. Verfasst von Yue Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Gynecology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui Province, China. Hauptthemen laut MEDLINE: Metformin, Ferroptosis, Ovarian Neoplasms, Repressor Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metformin (Met), a widely used type II diabetes medication, has shown anti-cancer properties in various cancers. RBMS3 is a tumor suppressor implicated in several cancers, including ovarian cancer. Ferroptosis, a novel form of programmed cell death, is gaining attention in cancer research. This study explores whether metformin induces ferroptosis and inhibits ovarian cancer progression through the RBMS3 pathway. We used a CCK-8 assay to determine the optimal metformin concentration for ovarian cancer cells. Metformin's effects were further evaluated using EdU assay and flow cytometry. To clarify its mechanism, we employed programmed cell death inhibitors and measured levels of MDA (Malondialdehyde), GSH (Glutathione), and Fe²⁺. Ferroptosis-related proteins and RBMS3 expression in ovarian cancer tissues and cells were assessed via RT-qPCR and Western blotting. A xenograft mouse model was used to observe metformin's effects on tumor growth. Metformin inhibited the viability of ovarian cancer A2780 cells, promoted ferroptosis, increased MDA and Fe²⁺ levels, and reduced GSH. It upregulated ferroptosis-related genes while downregulating GPX4 and SLC7A11. Although RBMS3 was reduced in cancer cells, metformin increased its expression, and silencing RBMS3 reversed metformin's effects. In vivo, metformin inhibited tumor growth, which was negated by RBMS3 silencing. Our findings suggest that metformin promotes ferroptosis and inhibits ovarian cancer progression by upregulating RBMS3, offering a promising direction for clinical application in ovarian cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Gynecology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui Province, China.
- Department of Oncology and Gynecology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui Province, China. Electronic address: yangbo@bbmc.edu.cn.
Zitieren
APA
Zhao, Y., Wang, Y., Zhang, X., Han, S., & Yang, B. (2025). Metformin-induced RBMS3 expression enhances ferroptosis and suppresses ovarian cancer progression. Reproductive Biology, 25(1), 100968. https://doi.org/10.1016/j.repbio.2024.100968
Vancouver
Zhao Y, Wang Y, Zhang X, Han S, Yang B. Metformin-induced RBMS3 expression enhances ferroptosis and suppresses ovarian cancer progression. Reproductive Biology. 2025;25(1):100968. doi:10.1016/j.repbio.2024.100968
BibTeX
@article{Zhao2025,
author = {Zhao, Yue and Wang, Yixiao and Zhang, Xinyi and Han, Shuqi and Yang, Bo},
title = {Metformin-induced RBMS3 expression enhances ferroptosis and suppresses ovarian cancer progression},
journal = {Reproductive Biology},
year = {2025},
volume = {25},
number = {1},
pages = {100968},
doi = {10.1016/j.repbio.2024.100968}
}
EUVIMED